Oric Pharmaceuticals
Kelli Habein is a highly experienced professional in the clinical supply chain and quality assurance fields, currently serving as Senior Manager of Clinical Supply Chain at ORIC Pharmaceuticals Inc. since April 2022. Previously, Kelli held various roles at Plexxikon Inc. from May 2014 to April 2022, including Manager of Clinical Drug Supply and Senior Clinical Drug Supply Chain Specialist, where responsibilities included evaluating drug supply needs, identifying risks, and managing inventories. Kelli also served as Senior Quality Assurance Specialist, ensuring compliance with cGMPs and FDA guidelines. Earlier experience includes a role at Mylan Specialty L.P. as Quality Assurance Document Change Control-Batch Record Issuance Specialist II. Kelli holds a Bachelor of Science in Business Administration with a focus on Management and Operations from the University of Phoenix.
This person is not in any offices
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.